United Therapeutics Corporation (UTHR) said Monday its long-term Phase 3 ADVANCE OUTCOMES study of ralinepag in pulmonary arterial hypertension met its primary endpoint, reducing the risk of clinical worsening by 55% compared with placebo.
The drug candidate showed durable efficacy in delaying disease progression, with 80% of patients on dual background therapy and 70% classified as World Health Organization/New York Heart Association Functional Class II at baseline.
The company said it plans to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of 2026.
Shares of United Therapeutics closed at $503.90 on Friday, up 0.06%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.